Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06018883 | Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer(PTCA199-3) | unknown | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06250972 | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer(PTCA199-11) | recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06958419 | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC) | recruiting | Phase 2 / Phase 3 | 286 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06841172 | Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC | recruiting | Phase 3 | 132 | Shandong Cancer Hospital and InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07098598 | Pancreatic Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 1, 2025 | clinicaltrials |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases(ASAC) | active not recruiting | Phase 2 / Phase 3 | 466 | Oslo University HospitalOTHER | 3 | Jul 31, 2025 | clinicaltrials |
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03434678 | Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection | completed | Phase 3 | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06441565 | Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06839092 | Prophylactic PIPAC in Patients With High-risk Colorectal Cancer(PROPAC) | not yet recruiting | Phase 3 | 160 | Jeremy MeyerOTHER | 0 | Jul 30, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT07074353 | Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer(CinClare-2) | not yet recruiting | Phase 3 | 360 | Zhejiang Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06793917 | Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 269 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 20, 2025 | clinicaltrials |
| NCT03828227 | QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.(COLAGE) | active not recruiting | Phase 3 | 49 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06199973 | Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan | active not recruiting | Phase 3 | 130 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07070622 | Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)(OPLAR) | recruiting | Phase 3 | 186 | West China HospitalOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2) | recruiting | Phase 3 | 220 | Tata Memorial CentreOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04922853 | Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer(COPEC) | active not recruiting | Phase 3 | 554 | West China HospitalOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06949033 | Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 668 | Zuoyi JiaoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT01815853 | Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer(Neo-CRAG) | completed | Phase 3 | 620 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06939439 | Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | active not recruiting | Phase 3 | 416 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07025239 | QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | not yet recruiting | Phase 3 | 430 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 17, 2025 | clinicaltrials |
| NCT07020247 | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study | recruiting | Phase 3 | 184 | West China HospitalOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT01804790 | Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer(Néofirinox) | completed | Phase 3 | 461 | UNICANCEROTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07016737 | Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy(ESO-Nanjing12) | enrolling by invitation | Phase 3 | 79 | Ye jinjunOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02804815 | Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours | active not recruiting | Phase 3 | 11,000 | University College, LondonOTHER | 2 | Jun 10, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04861558 | Efficacy of Hyperthermic Intraperitoneal Chemotherapy(EFFIPEC) | recruiting | Phase 3 | 213 | Uppsala UniversityOTHER | 2 | May 30, 2025 | clinicaltrials |
| NCT03206151 | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | completed | Phase 3 | 520 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT04328948 | A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC(ARMADILLO) | recruiting | Phase 3 | 280 | National Cancer Center, JapanOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT04856787 | A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC | terminated | Phase 2 / Phase 3 | 62 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT02467582 | Adjuvant Aspirin Treatment for Colon Cancer Patients | terminated | Phase 3 | 1,040 | Swiss Cancer InstituteOTHER | 4 | May 16, 2025 | clinicaltrials |
| NCT00806611 | Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer | completed | Phase 3 | 438 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06968221 | Bovine Reinforcement in Stomach, Colorectal and Lung Operation | recruiting | Phase 3 | 172 | Shanghai Cingularbio Co. LtdINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 / Phase 3 | 294 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT06966232 | Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers | recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma(SIRCCA) | terminated | Phase 2 / Phase 3 | 89 | Sirtex MedicalINDUSTRY | 8 | May 9, 2025 | clinicaltrials |
| NCT04068103 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | active not recruiting | Phase 2 / Phase 3 | 635 | NRG OncologyOTHER | 3 | May 7, 2025 | clinicaltrials |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | completed | Phase 3 | 131 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06959693 | A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 2 / Phase 3 | 590 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT00357682 | A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia(AspECT) | completed | Phase 3 | 2,557 | University of OxfordOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT05065957 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | recruiting | Phase 2 / Phase 3 | 180 | InnoPharmax Inc.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis(LIVERATION) | recruiting | Phase 3 | 471 | Can-Fite BioPharmaINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | not yet recruiting | Phase 3 | 616 | RemeGen Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2025source: clinicaltrials